Overview

Celecoxib in Treating Patients With Bladder Cancer

Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
This randomized phase IIb/III trial is studying celecoxib to see how well it works in preventing disease recurrence in patients who have bladder cancer. Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib may be an effective way to prevent the recurrence of bladder cancer
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Celecoxib